서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 60 of 68

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-10
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer
DOI
2008-01
Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
DOI
2008-02
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer
DOI
2008-12
Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients
DOI
2009
Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
DOI
2009-01
Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer

Sun, Jong-Mu; Lee, Keun-Wook; Kim, Jee Hyun; Kim, Yu Jung; Lee, Jae-Ho; Lee, Jong Seok; Lee, Choon-Taek; Yoon, Ho Il

JAPANESE JOURNAL OF CLINICAL ONCOLOGY; Vol.39 1; 27-32

DOI
2009-03
The role of PET/CT in detection of gastric cancer recurrence
DOI
2009-07
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
DOI
2009-08
Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer
DOI
2010-03
신생병원의 5년 유방암 치료 경험: 임상 데이터 웨어하우스를 이용한 분석
DOI
2010-09
Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer
DOI
2010-10
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
DOI
2011-07
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial
DOI
2012-08
ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy
DOI
2012-08
FGFR1 is amplified during the progression of in situto invasive breast carcinoma
view fileDOI
2013-07
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
DOI
2013-10
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
DOI
2014-03
Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients
DOI
2014-07
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
DOI
2014-09
Prediction of survival in terminally ill cancer patients at the time of terminal cancer diagnosis
DOI
2014-09
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2015-01
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
DOI
2015-06
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, Sung Hoon; Kim, Yu Jung; Kim, Se Hyun; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok

Journal of Cancer Research and Clinical Oncology, Vol.141 No.6, pp.1073-1081

DOI
2015-06
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
DOI
2016-05
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
DOI
2017-01
Post-bevacizumab clinical outcomes and the impact of early discontinuation of bevacizumab in patients with recurrent malignant glioma
DOI
2017-03
A prognostic model for patients with triple-negative breast cancer: Importance of the modified Nottingham prognostic index and age
DOI
2017-07
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
DOI
2017-09
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
DOI
2017-10
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
DOI
2017-12
Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study
DOI
2018-02
Hippocampus-sparing radiotherapy using volumetric modulated arc therapy (VMAT) to the primary brain tumor: the result of dosimetric study and neurocognitive function assessment
view fileDOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
DOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2018-08
Venom allergen-like protein 28 in Clonorchis sinensis: four epitopes on its surface and the potential role of Cys124 for its conformational stability

Lee, Myoung-Ro; Yoo, Won Gi; Kim, Yu Jung; Chung, Eun Ju; Cho, Shin-Hyeong; Ju, Jung-Won

Parasitology Research, Vol.117 No.8, pp.2521-2530

DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2018-10
BGJ398, a pan-FGFR inhibitor, overcomes paclitaxel resistance in urothelial carcinoma with FGFR1 overexpression
DOI
2018-10
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
DOI
2018-11
Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort
DOI
2018-11
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
DOI
2019-01
Epidermal growth factor receptor gene amplification predicts worse outcome in patients with surgically resected nonadenocarcinoma lung cancer

Chang, Hyun; Yang, Yaewon; Lee, Jong-Seok; Jheon, Sang-Hoon; Kim, Yu Jung; Chung, Jin-Haeng

Clinical Lung Cancer, Vol.20 No.1, pp.7-12.e1

DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
DOI
2019-01
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
DOI
2019-02
Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit
DOI
2019-05
Prognostic significance of metabolic parameters measured by F-18-FDG PET/CT in limited-stage small-cell lung carcinoma

Chang, Hyun; Lee, Soo Jin; Lim, Jin; Lee, Jong Seok; Kim, Yu Jung; Lee, Won Woo

Journal of Cancer Research and Clinical Oncology, Vol.145 No.5, pp.1361-1367

DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2020-05
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis
view fileDOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-09
Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2020-12
Cell-Mediated Immunogenicity of Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitors
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-10
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
DOI
2021-12
R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
DOI
1 2